JNJ-26481585
货号：
14088-50mg 基本售价：
9100.0 元 规格：
50 mg
产品信息
概述| 货号 | 14088-50mg |
| 描述 | JNJ-26481585 is a hydroxamate-based HDAC inhibitor that shows activity toward all HDAC enzymes with highest potency in vitro toward HDAC1 (IC50 = 0.11 nM).1 For other HDACs, IC50 values range from 0.33, 0.37, and 0.46 nM for HDACs 2, 11, and 10, respectively, to 32, 77, and 119 nM for HDACs 9, 6, and 7, respectively.1 JNJ-26481585 induces apoptosis and cell cycle arrest in multiple myeloma cells and complete tumor growth inhibition in Ras mutant HCT116 colon carcinoma or multiple myeloma xenografts.1,2 |
| 别名 | Quisinostat; |
性能| 供应商 | Cayman |
| 应用文献 |
1.Arts, J.,King, P.,Mariën, A., et al. JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin. Cancer. Res 15(22), 6841-6851 (2009).
2.Deleu, S.,Lemaire, M.,Arts, J., et al. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia 23(10), 1894-1903 (2009).
|
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 394.5 |
| 分子式 | C21H26N6O2 |
| CAS号 | 875320-29-9 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
